Skip to main content

Research Repository

Advanced Search

Drug Discovery against Acanthamoeba Infections: Present Knowledge and Unmet Needs

Elsheikha, Hany M.; Siddiqui, Ruqaiyyah; Khan, Naveed Ahmed


Ruqaiyyah Siddiqui

Naveed Ahmed Khan


Although major strides have been made in developing and testing various anti-acanthamoebic drugs, recurrent infections, inadequate treatment outcomes, health complications, and side effects associated with the use of currently available drugs necessitate the development of more effective and safe therapeutic regimens. For any new anti-acanthamoebic drugs to be more effective, they must have either superior potency and safety or at least comparable potency and an improved safety profile compared to the existing drugs. The development of the so-called ‘next-generation’ anti-acanthamoebic agents to address this challenge is an active area of research. Here, we review the current status of anti-acanthamoebic drugs and discuss recent progress in identifying novel pharmacological targets and new approaches, such as drug repurposing, development of small interfering RNA (siRNA)-based therapies and testing natural products and their derivatives. Some of the discussed approaches have the potential to change the therapeutic landscape of Acanthamoeba infections.


Elsheikha, H. M., Siddiqui, R., & Khan, N. A. (2020). Drug Discovery against Acanthamoeba Infections: Present Knowledge and Unmet Needs. Pathogens, 9(5),

Journal Article Type Article
Acceptance Date May 12, 2020
Online Publication Date May 22, 2020
Publication Date 2020-05
Deposit Date May 26, 2020
Publicly Available Date May 26, 2020
Journal Pathogens
Publisher MDPI
Peer Reviewed Peer Reviewed
Volume 9
Issue 5
Article Number 405
Public URL
Publisher URL


You might also like

Downloadable Citations